Weight change following diagnosis with psychosis: a retrospective cohort study in Greater Manchester, UK.
Affective psychosis
BMI
Longitudinal
Non-affective psychosis
Weight gain
Journal
Annals of general psychiatry
ISSN: 1744-859X
Titre abrégé: Ann Gen Psychiatry
Pays: England
ID NLM: 101236515
Informations de publication
Date de publication:
03 Jan 2024
03 Jan 2024
Historique:
received:
23
07
2023
accepted:
05
12
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
3
1
2024
Statut:
epublish
Résumé
Weight gain in the months/years after diagnosis/treatment of severe enduring mental illness (SMI) is a major predictor of future diabetes, dysmetabolic profile and increased risk of cardiometabolic diseases. There is limited data on the longer-term profile of weight change in people with a history of SMI and how this may differ between individuals. We here report a retrospective study on weight change over the 5 years following an SMI diagnosis in Greater Manchester UK, an ethnically and culturally diverse community, with particular focus on comparing non-affective psychosis (NAP) vs affective psychosis (AP) diagnoses. We undertook an anonymised search in the Greater Manchester Care Record (GMCR). We reviewed the health records of anyone who had been diagnosed for the first time with first episode psychosis, schizophrenia, schizoaffective disorder, delusional disorder (non-affective psychosis = NAP) or affective psychosis (AP). We analysed body mass index (BMI) change in the 5-year period following the first prescription of antipsychotic medication. All individuals had taken an antipsychotic agent for at least 3 months. The 5-year follow-up point was anywhere between 2003 and 2023. We identified 9125 people with the diagnoses above. NAP (n = 5618; 37.3% female) mean age 49.9 years; AP (n = 4131; 60.5% female) mean age 48.7 years. 27.0% of NAP were of non-White ethnicity vs 17.8% of AP individuals. A higher proportion of people diagnosed with NAP were in the highest quintile of social disadvantage 52.4% vs 39.5% for AP. There were no significant differences in baseline BMI profile. In a subsample with HbA1c data (n = 2103), mean HbA1c was higher in NAP at baseline (40.4 mmol/mol in NAP vs 36.7 mmol/mol for AP). At 5-year follow-up, there was similarity in both the overall % of individuals in the obese ≥ 30 kg/m The results of this real-world longitudinal cohort study suggest that the changes in BMI with treatment of non-affective psychosis vs bipolar disorder are not significantly different, while 43% maintain a healthy weight in the first 5 years following antipsychotic prescription.
Identifiants
pubmed: 38172807
doi: 10.1186/s12991-023-00485-8
pii: 10.1186/s12991-023-00485-8
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1Informations de copyright
© 2023. The Author(s).
Références
Heald AH, Martin JL, Payton T, Khalid L, Anderson SG, Narayanan RP, De Hert M, Yung A, Livingston M. Changes in metabolic parameters in patients with severe mental illness over a 10-year period: a retrospective cohort study. Aust NZ J Psychiatry. 2017;51:75.
doi: 10.1177/0004867415625817
Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16:1205–18.
doi: 10.1017/S1461145712001277
pubmed: 23199972
Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686–96.
doi: 10.1176/ajp.156.11.1686
pubmed: 10553730
Brandl EJ, Kennedy JL, Müller DJ. Pharmacogenetics of antipsychotics. Can J Psychiatry. 2014;59:76–88.
doi: 10.1177/070674371405900203
pubmed: 24881126
pmcid: 4079237
Cooper SJ, Reynolds GP, With expert co-authors (in alphabetical order), Barnes T, England E, Haddad PM, Heald A, Holt R, Lingford-Hughes A, Osborn D, McGowan O, Patel MX, Paton C, Reid P, Shiers D, Smith J. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 2016;30:717–48.
doi: 10.1177/0269881116645254
pubmed: 27147592
Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiat. 2014;71:1350–63.
doi: 10.1001/jamapsychiatry.2014.1314
Shrivastava A, Johnston ME. Weight-gain in psychiatric treatment: risks, implications, and strategies for prevention and management. Mens Sana Monogr. 2010;8:53–68.
doi: 10.4103/0973-1229.58819
pubmed: 21327170
pmcid: 3031940
Harrison RNS, Gaughran F, Murray RM, Lee SH, Cano JP, Dempster D, Curtis CJ, Dima D, Patel H, de Jong S, Breen G. Development of multivariable models to predict change in Body Mass Index within a clinical trial population of psychotic individuals. Sci Rep. 2017;7:14738.
doi: 10.1038/s41598-017-15137-7
pubmed: 29116126
pmcid: 5677086
https://gmwearebettertogether.com/research-and-planning/ . Accessed 3 July 2023.
Campforts B, Drukker M, Crins J, van Amelsvoort T, Bak M. Association between antipsychotic medication and clinically relevant weight change: meta-analysis. BJPsych Open. 2023;9(1): e18.
doi: 10.1192/bjo.2022.619
pubmed: 36651070
pmcid: 9885350
Anderson SG, Livingston M, Couchman L, Smith DJ, Connolly M, Miller J, Flanagan RJ, Heald AH. Sex differences in plasma clozapine and norclozapine concentrations in clinical practice and in relation to body mass index and plasma glucose concentrations: a retrospective survey. Ann Gen Psychiatry. 2015;14(14):39.
doi: 10.1186/s12991-015-0075-x
pubmed: 26583040
pmcid: 4650861
Heald A, Azadbakht N, Geary B, Conen S, Fachim H, Lee DCH, Geifman N, Farman S, Howes O, Whetton A, Deakin B. Application of SWATH mass spectrometry in the identification of circulating proteins does not predict future weight gain in early psychosis. Clin Proteomics. 2020;17:38.
doi: 10.1186/s12014-020-09299-2
pubmed: 33117088
pmcid: 7590460
Heald AH, Stedman M, Farman S, Khine C, Davies M, De Hert M, Taylor D. Links between the amount of antipsychotic medication prescribed per population at general practice level, local demographic factors and medication selection. BMC Psychiatry. 2020;20:528.
doi: 10.1186/s12888-020-02915-3
pubmed: 33160310
pmcid: 7648310
Heald A, Livingston M, Yung A, De Hert MA. Prescribing in schizophrenia and psychosis: Increasing polypharmacy over time. Hum Psychopharmacol. 2017;32(2): e2579.
doi: 10.1002/hup.2579
Remington G, Hahn MK, Agarwal SM, Chintoh A, Agid O. Schizophrenia: antipsychotics and drug development. Behav Brain Res. 2021;414: 113507.
doi: 10.1016/j.bbr.2021.113507
pubmed: 34352293
Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs. 2011;25:1035–59.
doi: 10.2165/11596300-000000000-00000
pubmed: 22133326
Heald AH, Stedman M, Daly C, Warner-Levy JJ, Livingston M, Hussain L, Anderson S. First episode psychosis and weight gain a longitudinal perspective in Cheshire UK: a comparison between individuals with nonaffective versus affective psychosis. Cardiovasc Endocrinol Metab. 2023;12(3): e0286.
doi: 10.1097/XCE.0000000000000286
pubmed: 37361477
pmcid: 10289689
Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231–41.
doi: 10.2147/NDT.S113099
pubmed: 28883731
pmcid: 5574691
Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004;66:51–7.
doi: 10.1016/S0920-9964(02)00498-X
pubmed: 14693352
Manschreck TC, Boshes RA. The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry. 2007;15:245–58.
doi: 10.1080/10673220701679838
pubmed: 17924259
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–23.
doi: 10.1056/NEJMoa051688
pubmed: 16172203
Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001;62:92–100.
doi: 10.4088/JCP.v62n0204
pubmed: 11247108
Jónsdóttir H, Opjordsmoen S, Birkenaes AB, Simonsen C, Engh JA, Ringen PA, Vaskinn A, Friis S, Sundet K, Andreassen OA. Predictors of medication adherence in patients with schizophrenia and bipolar disorder. Acta Psychiatr Scand. 2013;127:23–33.
doi: 10.1111/j.1600-0447.2012.01911.x
pubmed: 22900964
Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP, Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1–46.
doi: 10.4088/JCP.7090su1cj
pubmed: 19686636
Puhl RM, Himmelstein MS, Pearl RL. Weight stigma as a psychosocial contributor to obesity. Am Psychol. 2020;75(2):274–89.
doi: 10.1037/amp0000538
pubmed: 32053000
Seidell JC. Societal and personal costs of obesity. Exp Clin Endocrinol Diabetes. 1998;106(2):7–9.
pubmed: 9792474
Lester H, Marshall M, Jones P, Fowler D, Amos T, Khan N, Birchwood M. Views of young people in early intervention services for first-episode psychosis in England. Psychiatr Serv. 2011;62:882–7.
doi: 10.1176/ps.62.8.pss6208_0882
pubmed: 21807826
Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, Beck K, Natesan S, Efthimiou O, Cipriani A, Howes OD. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64–77.
doi: 10.1016/S2215-0366(19)30416-X
pubmed: 31860457
pmcid: 7029416
Firth J, Siddiqi N, Koyanagi A, Siskind D, Rosenbaum S, Galletly C, Allan S, Caneo C, Carney R, Carvalho AF, Chatterton ML, Correll CU, Curtis J, Gaughran F, Heald A, Hoare E, Jackson SE, Kisely S, Lovell K, Maj M, McGorry PD, Mihalopoulos C, Myles H, O’Donoghue B, Pillinger T, Sarris J, Schuch FB, Shiers D, Smith L, Solmi M, Suetani S, Taylor J, Teasdale SB, Thornicroft G, Torous J, Usherwood T, Vancampfort D, Veronese N, Ward PB, Yung AR, Killackey E, Stubbs B. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019;6:675.
doi: 10.1016/S2215-0366(19)30132-4
pubmed: 31324560
Barton BB, Segger F, Fischer K, Obermeier M, Musil R. Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19(3):295–314.
doi: 10.1080/14740338.2020.1713091
pubmed: 31952459
Ventriglio A, Gentile A, Stella E, Bellomo A. Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. Front Neurosci. 2013;9:297.
Waite F, Langman A, Mulhall S, Glogowska M, Hartmann-Boyce J, Aveyard P, Lennox B, Oxford Cognitive Approaches to Psychosis Patient Advisory Group, Kabir T, Freeman D. The psychological journey of weight gain in psychosis. Psychol Psychother. 2022;95:525–40.
doi: 10.1111/papt.12386
pubmed: 35137519
pmcid: 9304181
Bak M, Drukker M, Cortenraad S, Vandenberk E, Guloksuz S. Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: a meta-analysis. PLoS ONE. 2021;16: e0244944.
doi: 10.1371/journal.pone.0244944
pubmed: 33596211
pmcid: 7888647